ENDRA Life Sciences (NDRA) grants CFO 20,000 RSUs

Rhea-AI Filing Summary

ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, acquired 20,000 shares of common stock on January 21, 2026. The shares come from restricted stock units that were granted at a price of $0 per share and convert into common stock on a one-for-one basis. After this transaction, he beneficially owns 20,000 common shares directly. The RSUs are scheduled to vest in full on January 21, 2027, meaning the CFO will receive all underlying shares on that date if vesting conditions are met.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacroux Richard

(Last) (First) (Middle)

3600 GREEN COURT

SUITE 350

(Street)

ANN ARBOR MI 48105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDRA Life Sciences Inc. [ NDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		20,000(1)	A	$0	20,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

	/s/ Richard Jacroux by Coleman Wombwell, attorney-in-fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NDRA report for its CFO?

ENDRA Life Sciences Inc. reported that Chief Financial Officer Richard Jacroux acquired 20,000 shares of common stock on January 21, 2026 through a restricted stock unit grant at a price of $0 per share.

How many ENDRA (NDRA) shares does the CFO own after this Form 4?

Following the reported transaction, Chief Financial Officer Richard Jacroux beneficially owns 20,000 shares of ENDRA common stock, held directly.

What are the terms of the 20,000 RSUs reported by NDRA?

The 20,000 restricted stock units (RSUs) convert to ENDRA common stock on a one-for-one basis and were granted at a price of $0 per share.

When do the CFO’s RSUs in ENDRA Life Sciences vest?

The restricted stock units reported in this Form 4 will vest in full on January 21, 2027, at which point they convert into shares of common stock.

Is this NDRA Form 4 transaction a purchase in the open market?

No. The Form 4 shows an acquisition coded “A” of common stock through restricted stock units granted at $0 per share, rather than an open-market buy.

What role does the reporting person in this NDRA Form 4 hold?

The reporting person, Richard Jacroux, serves as Chief Financial Officer of ENDRA Life Sciences Inc., and filed the Form 4 as an officer of the company.